SNCA is a human gene. Variants in SNCA have been implicated in Parkinson's Disease (PARK6), Other Associations. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
Gene Symbol: PINK1
Also Known As: PARK6, PTEN-induced putative kinase 1
Gene ID (NCBI): 65018
Chromosomal Location: 1p36.23
PINK1 (PTEN Induced Kinase 1) is a serine/threonine-protein kinase encoded by the PINK1 gene, located on chromosome 1p36.23. It is primarily localized to the outer mitochondrial membrane and plays a critical role in mitochondrial quality control through the activation of parkin-mediated mitophagy [1][2]. Mutations in PINK1 cause autosomal recessive Parkinson's disease (PARK6), making it one of the most common genetic causes of early-onset PD [3].
¶ Protein Structure and Function
PINK1 contains:
- An N-terminal mitochondrial targeting sequence (MTS)
- A serine/threonine kinase domain
- A C-terminal regulatory domain
PINK1 is a mitochondrial serine/threonine-protein kinase that phosphorylates multiple substrates:
- Parkin (PRKN): PINK1 phosphorylates parkin at Ser65, activating its E3 ubiquitin ligase activity [4]
- Ubiquitin: Phosphorylates ubiquitin at Ser65, creating a phospho-ubiquitin signal that amplifies mitophagy [5]
- Mitochondrial proteins: Including TOM complex subunits and mitochondrial fusion proteins
Under normal conditions, PINK1 is imported into mitochondria and degraded. Under mitochondrial stress or damage:
- PINK1 accumulates on the outer mitochondrial membrane
- It phosphorylates parkin and ubiquitin
- Activated parkin ubiquitinates mitochondrial proteins
- Damaged mitochondria are targeted for autophagic degradation (mitophagy)
PINK1 is expressed in:
PINK1 mutations cause autosomal recessive early-onset Parkinson's disease:
- Age of onset: 30-50 years
- Clinical features: Tremor, bradykinesia, rigidity
- Good levodopa response
- Often presents with sleep disorders
- Alzheimer's disease: Altered PINK1 expression in AD brains [6]
- Cancer: Tumor suppressor functions reported
- Mitochondrial disorders: Role in metabolic diseases
- PINK1 activators: Small molecules to enhance PINK1 kinase activity
- Mitophagy modulators: Compounds that promote mitochondrial clearance
- Mitochondrial protectors: Prevent mitochondrial dysfunction
- Gene therapy approaches to deliver functional PINK1
- Phospho-mimetic parkin activators
- Mitochondrial dynamics modulators